Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Paul Silcocks et al.|The Lancet Oncology|2014Cited by 374
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinomaRichard Turkington, Richard D. Kennedy, Rosalie Douglas et al.|Gut|2019Cited by 27